Emcure Pharmaceuticals IPO analysis @ Chanakyanipothi.com , India`s Oldest & most Trusted Investment Blog.Operational since 8th December 1999, We are the Only Investment Platform in India, which has successfully completed 21 Years

Emcure Pharmaceuticals Grey Market News Today #
On
Grey Market Premium Rs. –
Application Rates :Rs. –
Subject to Rates : Rs. –

Emcure Pharmaceuticals Company Details
Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. It was ranked as (i) the 12th largest pharmaceutical company in India and (ii) the largest pharmaceutical company in India in the gynecology, blood related and HIV antivirals therapeutic areas, based on sales in India in the Financial Year 2021. Emcure is an R&D driven company with a differentiated product portfolio that includes orals, injectables and biologics, as well as an mRNA platform through which it is currently developing a COVID-19 vaccine, that has enabled it to reach a range of target markets across over 70 countries with a strong presence in Europe and Canada. Emcure is led by a Promoter Group with significant experience in the pharmaceutical industry who are supported by a strong professional management team. According to CRISIL, it is one of the fastest growing pharmaceutical companies in India as measured by the increase in its sales of pharmaceutical products in India.
According to CRISIL, between the Financial Year 2019 and the Financial Year 2021, its total sales in India grew at a CAGR of 11.28% from Rs 32,856.00 million to Rs40,686.00 million, outperforming the Indian pharmaceutical industry’s overall growth in sales in India, which grew at a CAGR of 5.78%. According to CRISIL, it is one of the market leaders in India in the HIV antivirals, gynecology and blood-related therapeutic areas, for which it held a domestic market share of 51.53%, 11.85% and 10.26%, respectively, as of March 31, 2021.
Its total sales outside India grew at a CAGR of 32.80% outperforming the Indian pharmaceutical industry’s overall growth in sales outside India, which grew at a CAGR of 14.90% & such
growth has been driven both organically, including through increasing penetration in these markets by launching new products and growing its existing brands, and inorganically, including through (i) strategic acquisitions of companies, such as of Marcan Pharmaceuticals in Canada and Tillomed Laboratories
in the United Kingdom ..For more information, click www.emcure.com

The Promoters of Emcure Pharmaceuticals
Satish Mehta &

Sunil Mehta

Emcure Pharmaceuticals IPO Main Objects
The Offer comprises of the Fresh Issue and Offer for Sale.
The Company proposes to utilise the Net Proceeds towards the following objects:
Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by the Company

Emcure Pharmaceuticals IPO Details
IPO opens on ? Dec, 2021
IPO closes on ? Dec,2021
Issue Type: Book Built Issue IPO
Issue : up to ? Shares /Rs 700 Crore
* Fresh Issue of ? Sh/ Rs.1100 Cr
* Offer for Sale Up to 18,168,356 Sh/ Rs. ? Cr

Face Value per share : Rs. 10

Emcure Pharmaceuticals IPO Price Band Per Equity Share: Rs. (?)
Emcure Pharmaceuticals IPO Retail Lot Size (?) Shares
Emcure Pharmaceuticals Listing will at BSE,NSE

Shares offered to
QIB (?%) ?Shares = Rs (?) Cr
NII (?%) ?Shares = Rs (?) Crs
RII (?%) ? Shares = Rs (?) Crs
Lot size: (?) Shares = (?) Forms
Min Retail Application : (?) Sh , Rs. (?)
Max Retail Application : (?) Sh, Rs (?)

Emcure Pharmaceuticals IPO Tentative timeTable
Emcure Pharmaceuticals IPO Allotment on ? Dec 2021
Unblocking of ASBA ? Dec 2021
Credit to Demat Accounts ? Dec 2021
Data Patterns Listing on ? Dec 2021

Emcure Pharmaceuticals IPO Financial Analytical Ratios
Earnings per Share 2019-20 Rs 4.62
Earnings per Share 2020-21,Rs 21.68
Earnings per Share 2021-22 6M Rs ?
Book Value of the Share as on 31.3.2021 Rs 125.68
Return on Net Worth: 19-20 4.37 %
Return on Net Worth: 20-21: 17.25 %
Return on Net Worth: 20-21 6M : ? %
Upper Price Band/last EPS:
Upper offer price/Book Value Ratio:
Equity Shares prior to the IPO : 180,852,116 Shares

Emcure Pharmaceuticals IPO Peer Comparison:
Abbott India @ PE Multiple of 53.79
Alkem Lab @ PE Multiple of 25.28
Biocon @ PE Multiple of 66.12
Cipla @ PE Multiple of 32.80
Dr. Reddy’s @ PE Multiple of 46.08
Torrent Pharma @ PE Multiple of 40.43

Emcure Pharmaceuticals IPO Lead Managers 
Axis Capital ,BofA Securities,Credit Suisse Securities (India),JM Financial ,BOB Capital Market
Registrar to Supriya LifeScience IPO
Linkintime India pvt ltd.

Registered Office of Emcure Pharmaceuticals
Emcure House, T-184, M.I.D.C., Bhosari, Pune – 411 026
Company Secretary & Compliance Officer : B. Renganathan

#This is only coverage of News related to Grey Market . We donot deal in Grey market premium, nor we recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.